GW Pharmaceuticals Plc
(NASDAQ : GWPH)

( )
GWPH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 2.25%93.515.5%$179.67m
VRXValeant Pharmaceuticals International, Inc. 0.13%30.3014.1%$178.29m
ICLRICON plc 4.47%205.204.2%$131.92m
CTLTCatalent, Inc. 1.02%111.032.1%$128.45m
GWPHGW Pharmaceuticals Plc 0.21%218.816.1%$124.34m
BHCBausch Health Cos., Inc. 0.13%30.300.0%$108.60m
UTHRUnited Therapeutics Corp. -0.55%201.6714.1%$97.68m
JAZZJazz Pharmaceuticals Plc 1.21%168.392.3%$90.22m
SAVACassava Sciences, Inc. -1.63%35.090.0%$67.46m
ARGXargenx SE 1.72%277.470.0%$51.25m
PRGOPerrigo Co. Plc 1.94%41.176.9%$37.55m
SAGESAGE Therapeutics, Inc. -0.23%75.507.6%$37.53m
AMRNAmarin Corp. Plc -1.96%5.011.5%$29.35m
PCRXPacira Biosciences, Inc. -4.45%66.349.9%$27.57m
ICPTIntercept Pharmaceuticals, Inc. -4.02%20.5516.8%$22.11m

Company Profile

GW Pharmaceuticals Plc operates as a biopharmaceutical company. The firm engages in the discovery, development and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.